Sagimet Biosciences
SGMT
48 hedge funds and large institutions have $130M invested in Sagimet Biosciences in 2023 Q3 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
72.88% more ownership
Funds ownership: 0% → 72.88% (+73%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$51.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.6M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$19.3M |
| 4 |
AG
Artal Group
Luxembourg
|
+$12.3M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$10.9M |
Top Sellers
SGMT Hedge Fund Activity: Q3 2023 in Review
48 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q3 2023, worth a combined $130M.
Buyers outnumbered sellers: 48 funds opened new SGMT positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $51.3M.
- 48 institutional investors held Sagimet Biosciences (SGMT) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $130M of Sagimet Biosciences stock for Q3 2023.
- 48 funds opened new Sagimet Biosciences positions in Q3 2023 and 0 closed out, a net change of +48 holders.
- The largest Sagimet Biosciences buyer in Q3 2023 was NEA Management Company, an estimated $51.3M added.
Based on aggregated 13F filings for Q3 2023.